Orient Europharma Co (ROCO:4120) ROCE %: -8.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4120 Orient Europharma Co Ltd ROCO:4120
60 GF Score
Price NT$44.40
GF Value NT$44.98
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Orient Europharma Co ROCE %?

Orient Europharma Co ROCO:4120 +0.91% 60 ROCE % is -8.00% as of Dec. 2025. GuruFocus rates ROCO:4120 with a GF Score™ of 60/100 and a GF Value™ of NT$44.98 (Fairly Valued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Orient Europharma Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -8.00%.

Orient Europharma Co  (ROCO:4120) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Orient Europharma Co ROCE % Related Terms

Orient Europharma Co ROCE % Historical Data

* Premium members only.

The historical data trend for Orient Europharma Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orient Europharma Co ROCE % Chart

Orient Europharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.06 -4.04 5.28 -0.30 -2.27

Orient Europharma Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.66 -3.77 5.30 -1.96 -8.00
ROCO:4120
60GF Score
Orient Europharma Co Ltd ROCO:4120
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orient Europharma Co ROCE % Calculation

Orient Europharma Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-198.968/( ( (11570.285 - 3307.964) + (12207.883 - 2914.54) )/ 2 )
=-198.968/( (8262.321+9293.343)/ 2 )
=-198.968/8777.832
=-2.27 %

Orient Europharma Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=-762.104/( ( (12428.023 - 2667.552) + (12207.883 - 2914.54) )/ 2 )
=-762.104/( ( 9760.471 + 9293.343 )/ 2 )
=-762.104/9526.907
=-8.00 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -8.00% mean?
Orient Europharma Co (ROCO:4120) has a ROCE % of -8.00% as of Dec. 2025.
Is Orient Europharma Co's ROCE % too high?
Orient Europharma Co's current ROCE % is -8.00%. Overall, Orient Europharma Co has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orient Europharma Co's ROCE % compare to ZTS and UTHR?
Orient Europharma Co's ROCE % of -8.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.06, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Europharma Co's current ROCE % is -8.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Europharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Europharma Co (ROCO:4120) is currently considered Fairly Valued. The stock's GF Value™ is NT$44.98, compared to a current price of NT$44.40 — trading 1.3% below its estimated fair value. The current ROCE % is -8.00%. Orient Europharma Co's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Orient Europharma Co (ROCO:4120), the current ROCE % is -8.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orient Europharma Co (ROCO:4120) Overvalued in 2026?

Based on GuruFocus' analysis, Orient Europharma Co stock appears to be undervalued. The current stock price of NT$44.40 is trading 1.3% below its estimated GF Value™ of NT$44.98. GuruFocus considers Orient Europharma Co to be Fairly Valued.

Key valuation signals for ROCO:4120:

  • ROCE %: -8.00%
  • GF Value™: NT$44.98 vs. price of NT$44.40 (1.3% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4120 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orient Europharma Co Business Description

Address 13th Floor, No. 128, Chengde Road, Section 6, Beitou District, Taipei, TWN, 112052
Orient Europharma Co Ltd is a Taiwan-based company engaged in the wholesale of Western Pharmaceutical and Medical Devices. The firm also manufactures drugs and medicines, Beverages, Cleaning Preparations, Cosmetics, Medical Devices, and Other Food Products. Its products cover various therapeutic areas, including the central nervous system, cardiovascular, diabetes, allergy, cosmetics, and health supplements. The company's segments include: Western Pharma BU which includes manufacture and sale of pharmaceutical and cosmetic products; and Nutricare BU includes sale of various nutrition supplements and consumable healthcare products. It derives maximum revenue from Western Pharma BU segment. Geographically, it operates in Taiwan, China, and Southeast Asia.
60GF Score

Get the complete analysis for ROCO:4120

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$44.40
Price
NT$44.98
GF Value